Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX)

Geode Capital Management LLC decreased its holdings in shares of Genelux Co. (NASDAQ:GNLX) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 303,318 shares of the company’s stock after selling 12,842 shares during the period. Geode Capital Management LLC owned approximately 0.88% of Genelux worth $716,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Apollon Wealth Management LLC boosted its stake in Genelux by 20.4% during the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares during the last quarter. LifeSteps Financial Inc. lifted its holdings in shares of Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after purchasing an additional 8,715 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Genelux during the fourth quarter valued at approximately $25,000. Raymond James Financial Inc. bought a new stake in Genelux during the fourth quarter worth $41,000. Finally, D.A. Davidson & CO. purchased a new stake in Genelux in the 4th quarter valued at $51,000. 37.33% of the stock is owned by institutional investors.

Genelux Trading Down 10.0 %

Shares of Genelux stock opened at $2.42 on Friday. The firm has a market capitalization of $83.74 million, a P/E ratio of -2.55 and a beta of -0.36. The business’s fifty day simple moving average is $3.15 and its 200 day simple moving average is $3.12. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $5.89.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Analysts predict that Genelux Co. will post -0.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Genelux in a report on Monday, March 31st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $18.25.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.